**Supplementary S1.** Chronic treatments and infection by SARS-CoV-2.

| | | PCR COVID-19 | | | |
|---|---|---|---|---|---|
| | [ALL] | Negative | Positive | Odds ratio | P value |
| | N=784 | N=439 | N=345 | | |
| ACE; ARB-II: | | | | | 0.216 |
| No | 466 (59.4%) | 252 (54.1%) | 214 (45.9%) | Ref. | |
| Yes | 318 (40.6%) | 187 (58.8%) | 131 (41.2%) | 0.83 [0.62;1.10] | |
| ANTIPSYCHOTICS: | | | | | 0.917 |
| No | 454 (57.9%) | 253 (55.7%) | 201 (44.3%) | Ref. | |
| Yes | 330 (42.1%) | 186 (56.4%) | 144 (43.6%) | 0.97 [0.73;1.30] | |
| ANTIDEPRESSANTS: | | | | | 0.515 |
| No | 400 (51.0%) | 229 (57.2%) | 171 (42.8%) | Ref. | |
| Yes | 384 (49.0%) | 210 (54.7%) | 174 (45.3%) | 1.11 [0.84;1.47] | |
| ANTICHOLINERGICS: | | | | | 0.222 |
| No | 763 (97.3%) | 424 (55.6%) | 339 (44.4%) | Ref. | |
| Yes | 21 (2.68%) | 15 (71.4%) | 6 (28.6%) | 0.51 [0.18;1.28] | |
| GABAERGICS: | | | | | 0.435 |
| No | 758 (96.7%) | 422 (55.7%) | 336 (44.3%) | Ref. | |
| Yes | 26 (3.32%) | 17 (65.4%) | 9 (34.6%) | 0.67 [0.28;1.50] | |
| PROTON PUMP INHIBITORS | | | | | 0.629 |
| No | 398 (50.8%) | 219 (55.0%) | 179 (45.0%) | Ref. | |
| Yes | 386 (49.2%) | 220 (57.0%) | 166 (43.0%) | 0.92 [0.70;1.22] | |
| NON-STEROIDAL ANTI-INFLA,MATORIES | | | | | 0.347 |
| No | 757 (96.6%) | 421 (55.6%) | 336 (44.4%) | Ref. | |
| Yes | 27 (3.44%) | 18 (66.7%) | 9 (33.3%) | 0.63 [0.27;1.40] | |
| BENZODIAZEPINES: | | | | | 0.685 |
| No | 471 (60.1%) | 267 (56.7%) | 204 (43.3%) | Ref. | |
| Yes | 313 (39.9%) | 172 (55.0%) | 141 (45.0%) | 1.07 [0.80;1.43] | |
| ANTIDIABETICS: | | | | | 0.955 |
| No | 654 (83.4%) | 367 (56.1%) | 287 (43.9%) | Ref. | |
| Yes | 130 (16.6%) | 72 (55.4%) | 58 (44.6%) | 1.03 [0.70;1.50] | |
| STATINS: | | | | | 0.097 |
| No | 604 (77.0%) | 328 (54.3%) | 276 (45.7%) | Ref. | |

| | | | | | |
|---|---|---|---|---|---|
| Yes | 180 (23.0%) | 111 (61.7%) | 69 (38.3%) | 0.74 [0.52;1.04] | |
| INHALERS: | | | | | 0.890 |
| No | 664 (84.7%) | 373 (56.2%) | 291 (43.8%) | Ref. | |
| Yes | 120 (15.3%) | 66 (55.0%) | 54 (45.0%) | 1.05 [0.71;1.55] | |
| LEVODOPA: | | | | | 0.222 |
| No | 763 (97.3%) | 424 (55.6%) | 339 (44.4%) | Ref. | |
| Yes | 21 (2.68%) | 15 (71.4%) | 6 (28.6%) | 0.51 [0.18;1.28] | |
| LEVOTHYROXINE | | | | | 0.739 |
| No | 702 (89.5%) | 395 (56.3%) | 307 (43.7%) | Ref. | |
| Yes | 82 (10.5%) | 44 (53.7%) | 38 (46.3%) | 1.11 [0.70;1.76] | |
| OPIOIDS | | | | | 0.401 |
| No | 676 (86.2%) | 374 (55.3%) | 302 (44.7%) | Ref. | |
| Yes | 108 (13.8%) | 65 (60.2%) | 43 (39.8%) | 0.82 [0.54;1.24] | |
| ANTIHYPERTENSIVES: | | | | | 0.021 |
| No | 260 (33.2%) | 130 (50.0%) | 130 (50.0%) | Ref. | |
| Yes | 524 (66.8%) | 309 (59.0%) | 215 (41.0%) | 0.70 [0.52;0.94] | |

**Supplementary S2.** Chronic drugs and mortality by SARS-CoV-2.

| | [ALL] | No exitus | Exitus | Odds ratio | P value |
|---|---|---|---|---|---|
| | N=345 | N=258 | N=87 | | |
| ACE_ARB-II: | | | | | 1.000 |
| No | 214 (62.0%) | 160 (74.8%) | 54 (25.2%) | Ref. | |
| Yes | 131 (38.0%) | 98 (74.8%) | 33 (25.2%) | 1.00 [0.60;1.64] | |
| ANTIPSYCHOTICS | | | | | 0.293 |
| No | 201 (58.3%) | 155 (77.1%) | 46 (22.9%) | Ref. | |
| Yes | 144 (41.7%) | 103 (71.5%) | 41 (28.5%) | 1.34 [0.82;2.19] | |
| ANTIDEPRESSANTS | | | | | 0.733 |
| No | 171 (49.6%) | 126 (73.7%) | 45 (26.3%) | Ref. | |
| Yes | 174 (50.4%) | 132 (75.9%) | 42 (24.1%) | 0.89 [0.55;1.45] | |
| ANTICHOLINERGICS: | | | | | 0.171 |
| No | 339 (98.3%) | 255 (75.2%) | 84 (24.8%) | Ref. | |
| Yes | 6 (1.74%) | 3 (50.0%) | 3 (50.0%) | 3.02 [0.51;17.9] | |
| GABAERGICS: | | | | | 0.459 |
| No | 336 (97.4%) | 250 (74.4%) | 86 (25.6%) | Ref. | |
| Yes | 9 (2.61%) | 8 (88.9%) | 1 (11.1%) | 0.41 [0.02;2.32] | |
| PROTON PUMP INHIBITORS | | | | | 0.099 |
| No | 179 (51.9%) | 141 (78.8%) | 38 (21.2%) | Ref. | |
| Yes | 166 (48.1%) | 117 (70.5%) | 49 (29.5%) | 1.55 [0.95;2.54] | |
| NON-STEROIDAL ANTI-INFLAMMATORIES | | | | | 0.238 |
| No | 336 (97.4%) | 253 (75.3%) | 83 (24.7%) | Ref. | |
| Yes | 9 (2.61%) | 5 (55.6%) | 4 (44.4%) | 2.45 [0.57;9.82] | |
| BENZODIAZEPINES: | | | | | 0.127 |
| No | 204 (59.1%) | 146 (71.6%) | 58 (28.4%) | Ref. | |
| Yes | 141 (40.9%) | 112 (79.4%) | 29 (20.6%) | 0.65 [0.39;1.08] | |
| ANTIDIABETICS: | | | | | 0.089 |
| No | 287 (83.2%) | 209 (72.8%) | 78 (27.2%) | Ref. | |
| Yes | 58 (16.8%) | 49 (84.5%) | 9 (15.5%) | 0.50 [0.22;1.02] | |
| STATINS: | | | | | 0.337 |
| No | 276 (80.0%) | 210 (76.1%) | 66 (23.9%) | Ref. | |
| Yes | 69 (20.0%) | 48 (69.6%) | 21 (30.4%) | 1.39 [0.77;2.48] | |

| | | | | | |
|---|---|---|---|---|---|
| INHALERS: | | | | | 0.521 |
| No | 291 (84.3%) | 220 (75.6%) | 71 (24.4%) | Ref. | |
| Yes | 54 (15.7%) | 38 (70.4%) | 16 (29.6%) | 1.31 [0.67;2.46] | |
| LEVODOPA: | | | | | 0.171 |
| No | 339 (98.3%) | 255 (75.2%) | 84 (24.8%) | Ref. | |
| Yes | 6 (1.74%) | 3 (50.0%) | 3 (50.0%) | 3.02 [0.51;17.9] | |
| LEVOTHYROXINE | | | | | 0.974 |
| No | 307 (89.0%) | 229 (74.6%) | 78 (25.4%) | Ref. | |
| Yes | 38 (11.0%) | 29 (76.3%) | 9 (23.7%) | 0.92 [0.39;1.97] | |
| OPIOIDS | | | | | 0.210 |
| No | 302 (87.5%) | 222 (73.5%) | 80 (26.5%) | Ref. | |
| Yes | 43 (12.5%) | 36 (83.7%) | 7 (16.3%) | 0.55 [0.21;1.22] | |
| ANTIHYPERTENSIVES | | | | | 1.000 |
| No | 130 (37.7%) | 97 (74.6%) | 33 (25.4%) | Ref. | |
| Yes | 215 (62.3%) | 161 (74.9%) | 54 (25.1%) | 0.98 [0.60;1.64] | |

**Supplementary S3.** Acute treatment and mortality by SARS-CoV-2.

| | [ALL] | No exitus | Exitus | Odd ratio | P value |
|---|---|---|---|---|---|
| | N=345 | N=258 | N=87 | | |
| TREATMENT WITH CORTICOIDS | | | | | 0.181 |
| No | 284 (82.3%) | 217 (76.4%) | 67 (23.6%) | Ref. | |
| Yes | 61 (17.7%) | 41 (67.2%) | 20 (32.8%) | 1.58 [0.85;2.87] | |
| TYPES OF CORTICOIDS: | | | | | 0.227 |
| Prednisone | 13 (21.3%) | 11 (84.6%) | 2 (15.4%) | Ref. | |
| Methylprednisolone | 46 (75.4%) | 28 (60.9%) | 18 (39.1%) | . [.;.] | |
| Dexametasone | 2 (3.28%) | 2 (100%) | 0 (0.00%) | . [.;.] | |